'When I met Chloe she was dead': one girl, four hearts and an NHS miracle
Chloe Narbonne ’s heart failed when she was 11, starting a near-hopeless fight for survival. A year on from groundbreaking surgery, she is alive and this is her storyRevealed: girl of 13 is first child in Britain to receive artificial heart“By the time I met Chloe she was dead,” André Simon says matter-of-factly. “I told her parents clearly that she didn’t really have a chance to survive. What I was proposing gave her a theoretical chance.” He pauses. “But I also said that the operation might just prolong her agony and su ffering – I didn’t even know if she would survive it – and that it was OK just to let her go.”Simon, one of the world ’s leading heart and lung specialists, is recalling the conversation he had at the beginning of May last year with Fabienne Narbonne and Todd Jancey that led to him implanting an artificial heart inside their 12-year-old daughter Chloe. “It was an emotional meeting, it was tense, it was horrible . They were trying to be calm but they were extremely anxious and were holding on to each other for support. They put their last hopes in me and they prayed for a miracle.”Continue reading...
AbstractMucopolysaccharidoses (MPS) are a group of hereditary disorders caused by lysosomal storage of glycosaminoglycans (GAGs) and characterized by a wide variability of phenotypes from severe fetal-neonatal forms to attenuated diseases diagnosed in adult individuals. The clinical picture generally worsens with age due to progressive storage involving mucosal tissue, upper airways and lungs, bones and joints, central and peripheral nervous system, heart, liver, eye, and ear. Cardiac storage of GAGs involves valves, heart muscle, and vessels (particularly the coronary arteries), and can be specific in relation to differen...
CRITICAL CARE CLINICS
Long-term outcomes after lung transplantation (LTx) remain inferior to other solid organs such as heart transplantation. This is largely a result of a high prevalence of chronic lung allograft dysfunction (CLAD), affecting approximately 50% of transplanted patients at 5 years post-transplant.1 Although Bronchiolitis Obliterans Syndrome (BOS) is the major clinical phenotype of CLAD (occurring in 70% of CLAD patients), Restrictive Allograft Syndrome (RAS), the other CLAD phenotype (30%), has a worse survival following diagnosis.
Since the Fontan operation was first performed in 1968, the procedure has been refined to afford the best long-term outcome for patients with single ventricle physiology, with recent studies showing 70% freedom from Fontan failure including the need for cardiac transplant at 20 years.1 Despite these improvements, the inherent physiology of the Fontan palliation with passive venous blood flow from the body to the pulmonary arteries can result in a variety of complications related to chronic venous congestion and low cardiac output.
Elevated blood pressure (BP) has been linked to adverse events during left ventricular assist device support. We aimed to investigate the association between outpatient BP and stroke or suspected pump thrombosis among HeartMate II (HMII) recipients.
The objective of the present study was to develop a method to improve the retention of hiPSCs in the myocardium for cardiac therapy.
This retrospective analysis evaluates a standardized echocardiographic assessment and an invasive technique for patient selection for successful continuous flow left ventricular assist device (cf-LVAD) explantation.